IRD (Opus Genetics) Interest Expense: $-2.12 Mil (TTM As of Mar. 2026)

What is Opus Genetics Interest Expense?

Opus Genetics IRD +7.38% 24 Interest Expense is $-2.12 Mil as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Opus Genetics's interest expense for the three months ended in Mar. 2026 was $ -0.65 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Opus Genetics's Operating Income for the three months ended in Mar. 2026 was $ -14.36 Mil. Opus Genetics's Interest Expense for the three months ended in Mar. 2026 was $ -0.65 Mil. Opus Genetics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Opus Genetics (NAS:IRD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Opus Genetics's Interest Expense for the three months ended in Mar. 2026 was $-0.65 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-14.36 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $1.20 Mil.

Opus Genetics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Opus Genetics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Opus Genetics Interest Expense Historical Data

* Premium members only.

The historical data trend for Opus Genetics's Interest Expense can be seen below:

Opus Genetics Interest Expense Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.00

-0.01

-1.33

0.00

-1.47

Opus Genetics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-1.37	0.00	-0.07	-1.40	-0.65

24GF Score

Opus Genetics Inc IRD

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Opus Genetics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.12 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-2.12 Mil mean?

Opus Genetics (IRD) has a Interest Expense of $-2.12 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Opus Genetics and its competitors.

Is Opus Genetics' Interest Expense too high?

Opus Genetics' current Interest Expense is $-2.12 Mil. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Opus Genetics' Interest Expense compare to IFRX and RGNX?

Opus Genetics' Interest Expense of $-2.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Opus Genetics and its competitors. Opus Genetics's current Interest Expense is $-2.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Opus Genetics stock overvalued right now?

Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.00 — trading 981.1% above its estimated fair value. The current Interest Expense is $-2.12 Mil. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Opus Genetics (IRD), the current Interest Expense is $-2.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $4.00 is trading 981.1% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

Interest Expense: $-2.12 Mil
GF Value™: $0.37 vs. price of $4.00 (981.1% above fair value)
GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Industry Healthcare Biotechnology

Comparable Companies IFRX RGNX LRMR GLSI NAUT PBYI PALI NMRA NWBO PROK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges R3X1:Germany

Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713

Website https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

24GF Score

Get the complete analysis for IRD

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00

Price

$0.37

GF Value

View IRD Analysis

See Interest Expense data for all stocks →